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Abstract
There are several unresolved issues through out the literature regarding the entity of primary lung lymphoma.
Extensive literature review of this uncommon pathology is carried out.
By taking into consideration the reported experience, the author discuss the classification, clinical features,
histological differential diagnosis, prognostic criteria, therapeutic management and outcome of primary lung
parenchyma lymphocytic infiltrates.
Introduction
P r i m a r yL u n gL y m p h o m a( P L L )i sar a r ee n t i t y( 0 . 4 %o f
all lymphomas [1] & 3.6% of non- Hodgkins lymphomas
[2]) of heterogenous group of patients with some com-
mon characteristics: 1) difficult to be diagnosed due to an
indolent course (with a tendency to relapse) with a non
specific clinical and radiological presentation 2) low diag-
nostic yield and 3) sometimes difficult to differentiate
from pseudo-lymphomas and 4)overall good outcome
especially in disease amenable to surgical resection.
The main diagnostic criterion for PLL is the absence of
extra-pulmonary involvement. That means unilateral or
bilateral involvement of the lung with or without hilar or
mediastinal lumph node involvement and with or with-
out chest wall involvement [3]. Therefore, in patients
with biopsy-proven lymphoma of the lung, PLL is diag-
nosed if extra-pulmonary involvement is ruled out.
In this article we aim to review the literature in order
to delineate from the surgeons prospective, the overall
experience of the rare entity of PLL and also to bring
up to date the variables leading to a favorable outcome
following surgery.
Materials and methods
Pertinent medical literature in the English language was
identified through a Medline computerized literature search
and a manual search of selected articles using as Key-
words: Primary pulmonary Lymphoma, Lung Lymphoma,
Pseudolymphoma of the lung, Non-Hodgkin lymphoma of
the lung or extranodal lymphoma. The search terms were
combined using the Boolean operator term “or” to find all
abstracts pertaining to the chosen search terms. These indi-
vidual terms were then combined using the Boolean opera-
tor term “and” to find articles that contained information of
all search terms (as per Greenhaligh et al) [4]. The reference
lists of articles found through these searches were also
reviewed for relevant articles. Links provided on the web
sites of published articles were searched for relevant articles.
The primary search yielded 81 relevant articles. Of those 14
were excluded as they pertained to pseudolymphoma.
The Ann Arbor pulmonary lymphoma staging system
was used for classification
Stage
IE: Lung only, could be bilateral
II 1E: Lung and hilar lymph nodes
II 2E: Lung and mediastinal lymph nodes
II 2EW: Lung & chest wall or diaphragm
III: lung and lymph nodes below the diaphragm
IV: diffuse
Characteristics of the various reports
We reviewed the reported literature from 1966 to 2007.
We divide the reports into 2 groups. The first group
(Table 1 [5-62]) contains case reports with fewer patients
compare to the second group (Table 2 [63-71]).
Results
Group A
58 reports were identified and reviewed. There were 309
cases of PLL. The largest series in this group [58]
included 31 patients.
Correspondence: hparissis@yahoo.co.uk
Cardiothoracic Dept, Royal Victoria Hospital, Belfast, Northern Ireland
Parissis Journal of Cardiothoracic Surgery 2011, 6:23
http://www.cardiothoracicsurgery.org/content/6/1/23
© 2011 Parissis; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Table 1 Published Studies with small number of patients nHL: Non Hodgkin Lymphoma MALToma: mucosa-associated
lymphoid tissue
Author Year Journal Number nHL MALT Comments/Outcome
Gao J [5] 2002 Zhonghua Jie He
He Hu Xi Za Zhi
6 Misdiagnosis is common. Persistent cough is the most
common symptom
Zhang L [6] 2006 Zhonghua Wai Ke
Za Zhi
10 8 3 cases IE, 2 cases II 1E, 2 cases II 2E and 1 case of II 2EW. All
patients had Pneumonectomy & ChemoTx. Survival > 17
months. Advanced (stage II 2E) B-cell low grade and Hodgkin
disease lead to poor prognosis
Tian XL [7] 2008 Zhonghua Jie He
He Hu Xi Za Zhi
18 7 9 CT features: nodules 14/18, Pleural effusion 5/18. Treatment
with Surgery & CTx/RTx. Survival > 11 months: 13 pts, with
one death and 4 patients lost to follow up
Varona JF [8] 2005 Tumori 6 6 Mono-CTx treatment with alkylating agents. The authors
suggest that the outcome is favorable whatever the treatment
modalities
Peterson H [9] 1985 Cancer 6 5 Authors suggest that the treatment is surgical resection and
that Rtx and CTx are used when residual disease is present
after surgery. Median time to death:48,6 months
Muller C [10] 1990 Rev Pneumol Clin 9 Treatment is surgical in localized forms; there is no firmly
established treatment in extensive forms
Mu XD [11] 2007 Beijing Da Xue
Xue Bao
1 1 MALT with features: consolidation of right middle lobe and
left lower lobe, left pleural effusion with monocytes,
monoclonal protein in the electrophoresis of serum, CD20
positive
Natali F [12] 1984 Rev Pneumol Clin 2 2 Discussion about PLL related diseases with a varying degree
of malignancy: interstitial lymphocytic pneumonitis ILP,
pseudolymphoma PL, lymphomatoid granulomatosis LYG
Deng L [13] 2003 Zhonghua Jie He
He Hu Xi Za Zhi
3 3 Radiological features of 3 cases and the role of percutaneous
biopsy
Nakachi S [14] 2007 Gan To Kagaku
Ryoho
2 2 cases of PPHodgkinL
Martinez RC [15] 2004 1 1 PPL presenting as a pulmonary mass with cavitation
Colby TV [16] 1982 20 20?
Toh HC [17] 1997 Leuk Lymphoma 11 11 Mean age 50. Lower lobe involvement was the commonest.
Small lymphocytic lymphoma was the most common. Good
symptom control and radiologic response was achieved with
chemotherapy
Marchevsky A [18] 1983 Cancer 5 Criteria for pseudolymphoma Vs PLL. 167 Cases in the
literature were analyzed
Morisako T [19] 1998 Nihon Kokyuki
Gakkai Zasshi
6 6 Southern blot analysis of lung biopsy: rearrangement of a
heavy chain gene
Kim JH [20] 2004 Jpn J Clin Oncol 24 9 15 50% of the patients were asymptomatic at presentation.
Bronchoscopy: 30% yield, 67% needed surgical procedure for
diagnosis. Overall survival at 3 years: 86%
Addis BJ [21] 1988 Histopathology 15 The diagnosis was based in 13 cases: on Light chain restriction
Arinc S [22] 2006 Tuberk Toraks Review paper on the current approach in PLL
Xu HY [23] 2007 Chin Med J 12 12 Diagnosis and treatment of MALTomas. 2 pts also had gastric
MALTS. Operation was performed on 6 patients. 4 pts treated
with Chemo alone. Mean survival 71.3 months. One patient
experience recurrence 152 months following operation.
Several treatment methods can be used to achieve good
outcomes
Pagani M [24] 2007 Tumori 1 1 Single case of right hilar LL.
Cao MS [25] 2008 Zhonghua Jie He
He Hu Xi Za Zhi
2 cases of NK/T cell L.
Also Literature review
of 3 cases
Aggressive tumors. Contrary to nHL most patients presents
with symptoms.
Pleural effusions 4/5. Ebstein-Barr was positive in 3/5. Those
tumors are CD56(+), CD3(+) but CD20(-). Most pts died within
6/12.
Baas AA [26] 1986 Eur J Respir Dis 1 1 Single case of a 49 y old man with multiple ill defined
densities in both lungs treated successfully with
Chemotherapy
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Ziade N [27] 2005 J Med Liban 1 1 Single case of PLL in an elderly patient
Habermann TM
[28]
1999 Semin Oncol Review article with an emphasis to observations in the clinical
management and treatment of PLL
Uematsu M [29] 1997 Kyobu Geka 1 1 PLL of Rt middle lobe treated with lobectomy
Tillawi IS [30] 2007 Saudi Med J 2 2 cases of P Hodgkin lymphoma in young patients. CD30 and
CD15 positive in RS cells were detected.
Chu HQ [31] 2007 Zhonghua Jie He
He Hu Xi Za Zhi
13 13 MALT is more common in middle age males. Variable
radiographic features; bilateral disease in more than 50% of
the cases
Le Tourneau A
[32]
1983 Hamatol Oncol 15 15 Reference to Kiel- Lennert histo pathological classification.
Association of PLL of B type and dysimmune disease
Loh KC [33] 1994 Ann Acad Med
Singapore
3 3 Interestingly, despite nodal involvement all patients had
surgical resections and adjuvant ChTx. All 3 alive at 92, 51 and
12 months
Cordier JF [34] 1984 Rev Mal Respir 4 The article raises the possible hypothesis that
pseudolymphoma may be the initial step in a large spectrum
ranging from benign to malignant primary lymphoproliferative
lung disorders
Watanabe J [35] 1987 Jpn J Med 1 1 The diagnostic value of surface marker analysis in primary B
cell lung lymphoma is emphasized
Toishi M [36] 2004 Kyobu Geka 2 2 Report of 2 cases of MALToma treated with Surgery and post
op RadioTherapy
Jayet A [37] 1980 Helv Chir Acta 10 This report emphasizes the fact that surgical treatment of PLL
has to be “economical” due to the fact that frequent
recurrences (sometimes bilateral) could be encountered
Kuroishi S [38] 2003 Nihon Kokyuki
Gakkai Zasshi
1 1 A case of a lingular lobe PLL that relapsed with diffuse
micronodular pattern 7 years following surgical resection
Sakula A [39] 1979 Postgrad Med J 1 1 A single case report
Hashizume T [40] 1997 Nihon Kyobu
Shikkan Gakkai
Zasshi
1 1 A single case report of PLL presented with bilateral infiltrative
shadows
Gouldesbrough
DR [41]
1988 Histopathology 1 A single case of PLL diagnosed by bronchial cytology and
immunocytochemistry
Bosanko CM [42] 1991 J Comput Assist
Tomogr
1 1 A single case report presented as an asymptomatic chronic
lobar consolidation
Chee YC [43] 1986 Ann Acad Med
Singapore
1 Report of a Pseudolymphoma case with a biclonal
gammopathy
Bolton- Maggs PH
[44]
1993 Thorax 2 2 Report of 2 cases of MALTomas, giving emphasis on the
varied clinical and radiological features
Xu TR [45] 1987 Zhonghua Jie He
He Hu Xi Za Zhi
2 2 Report of 2 cases of MALTomas, giving emphasis on the
varied clinical and pathological features
Konig G [46] 1986 Prax Klin Pneumol 1 The role of BAL in diagnosis of PLL
Ehrenstein F [47] 1966 J. Thorac
Cardiovasc Surg
2 2 2 cases of PLL
Tamura A [48] 1995 Jpn J Clin Oncol 24 24 PLL: relationship between clinical features and pathologic
findings Pulmonary LL were divided into 4 groups Bcell
tumors composed of small to medium size lymphoid cells
have the best prognosis
Sakuraba M [49] 2000 Nihon Kokyuki
Gakkai Zasshi
3 2 Report of 3 cases
Abe Y [50] 1998 Nihon Kokyuki
Gakkai Zasshi
1 1 One case of MALToma diagnosed with flow cytometer
analysis, monoclonal gammopathy and Southern blot analysis
of the heavy chain of the immunoglobulin gene
Umino T [51] 1993 Nihon Kokyuki
Gakkai Zasshi
1 1 A case of PLL diagnosed with: High serum IgG, BAL showing
45% plasma cells and 18% lympocytes, CD19(+), IgG/albumin
ratio 13 times higher and IL-6/albumin ratio29 times higher in
BAL than serum. The PCR on the DNA extracted from the
surgical specimen showed rearrangement of the
immunoglobulin heavy chain gene
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of PLL with mucosa-associated lymphoid tissue (MAL-
Tomas) being 70-80%. Hodgkin lymphoma was reported
in a small number of cases 1.5-2.4%.
T h ec o u r s eo ft h ed i s e a s ei sl o n ga n di n d o l e n ts p a n -
ning from 1.5 to 108 months [31].
Radiological appearance have shown that non specific
patchy opacities or mass-like consolidation was the case
in the majority of the patients (up to 68%) and multiple
nodules in more than 50% of the cases. [31,57,58].
Nodal involvement (stage II1E, II2E) was reported in
35%-45% of the cases [6,18,58].
Bronchoscopy obtained a diagnostic yield in 30%-40%
[20,48] of the cases and invasive surgical procedure
revealed the diagnosis in up to 70% of the cases [20].
There was no uniform protocol throughout the literature
regarding the indications for surgery. Despite nodal invol-
vement (stage II 1E and 2E) surgery was advocated in few
studies [33] and some authors concluded that several treat-
ment methods can be used to achieve good outcomes [23].
Group B
The second group consisted of 506 reported cases of
PLL.
In the majority of the studies the male to female ratio
is variable (from 1/1 [68] to 1/2 [70]). Average age
of disease presentation is 53±12 years [65,68-70]. 83% of
the patients have been reported to be above 40 years of
age [65].
Symptoms are present in 2/3 of the patients (62.5% to
78% of patients) [69,70]. The mean duration of symp-
toms was 5 months [65]. Mild symptoms with no resol-
ving consolidation should be managed with a high index
of suspicion.
Again, nHL consist the majority of PLL with MALTo-
mas being 60-78% [69-71].
The radiographic appearance shows nodules or mass
lesions in 60-72%, [69,70]. Single lesions are present in
55% of the cases [65]. Multip l en o d u l e sa r ep r e s e n ti n
40% of the patients [65,67]. Bilateral disease varies in dif-
ferent reports: 21%. [68], 27% [65], 39% [70], 44% [69].
Nodal involvement (stage II1E, II2E) was reported
in 28 to 39% of the cases [65,69] and Pleural effusions
15-22% [69,70].
There was again, no uniform protocol throughout the
literature regarding the indications for surgery. Never-
theless, surgery was advocated in 60-70% of the
patients. The MALToma patients tend to have complete
Table 1 Published Studies with small number of patients nHL: Non Hodgkin Lymphoma MALToma: mucosa-associated
lymphoid tissue (Continued)
Zinzani PL [52] 2003 12 MALTomas
Herbert A [53] 1984 Hum Pathol 9 9 The authors claim that histologic evidence of lymph node
involvement is unusual even in the presence of mediastinal or
pleural infiltration
Davis WB [54] 1987 Chest 1 1 Report of one case of bilateral interstitial infiltrates with
lymhocytic alveolitis on the BAL
Pisani RJ [55] 1990 Mayo Clin Proc 1 1 Report of the first case wherein PLL was diagnosed with
immunohistologic (less diagnostic for T cell lymphomas) and
molecular biologic studies of BAL.
Sprague RI [56] 1989 Chest 1 A case of an elderly female with multiple densities on CXR.
Diagnosis was made with transthoracic fine needle aspiration
Julsrud PR [57] 1978 Radiology Pseudolymphoma & lymphocytic interstitial pneumonitis have
a different radiographic pattern to lymphocytic lymphoma
Lewis ER [58] 1991 AJR Am J
Roentgenol
31 CT findings of pulmonary lymphoma: masslike consolidation
(68%), multiple nodules (55%). 2/3 of the patients have more
than one type of CT finding simultaneously
Bellotti M [59] 1987 Respiration 5 Report a series of 5 PLL out of 9 lymphomas involving the
lung
Kilgore TL [60] 1983 Chest 4 4 cases of endobronchial nHL. The authors claim that all the
patients had disseminated disease at the time of
endobronchial involvement.
Rose RM [61] 1986 Cancer 3 3 cases of endobronchial nHL. The authors have identified 2
patterns of endobronchial involvement: Type 1 characterized
by submucosal infiltrates occurring in the presence of
disseminated disease and Type 2 whereby the central airway
is involved by a solitary mass in the absence of disease
elsewhere.
Oka M [62] 1988 Am Rev Respir Dis 1 A case report, whereby the diagnosis of PLL was made 5 years
after initial presentation
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had more favorable outcome [71].
Diagnosis
The role of monoclonal protein in the electrophoresis of
serum protein: ie. Serum IgG >5000 mgr/dl has been
stated in some reports [19,21,51]. Stained for Kappa &
Lambda chains, using the immunoperoxidase technique
on paraffin sections has been reported. Serum protein
electrophoresis abnormalities could be present in up to
33% of the cases [65]. Serum or immunofluorescence
monoclonal gammopathy should exclude pseudoL.
Table 2 Published Studies with large number of patients
Author Year Journal Number of
Patients
Characteristics Appearance Recurrence
Survival
Koss MN [63] 1983 Hum Pathol 161 14%
pseudolymphomas
138 nHL.
Elderly, mainly
asymptomatic
Most cases: Solitary
nodule or infiltrate
Most recurrences
occur within 3
years
18 out of 101 patients
died from tumor. Pleural
effusion was a predictor
of mortality
Turner RR [64] 1984 Cancer 47 28 cases of
PLL
Good prognosis: 1
patient died in 4 years
follow up
L Hoste R [65] 1984 Cancer 36 nHL Mean age 53
y. More than
80% of
patients >40 y
Single lesions 20 cases.
Multiple: 16. Unilateral
26, bilateral 10. IE:24,
II1E:2, II2E:8, II2EW:2
58% LPI
33% of LPI recur.
50% of non LPI
recur. Average
time to
recurrence:69
months
33% died, most non LPI.
No survival difference
among cases grouped
according to stage(IE Vs
II2E). For stage IE LPI
group did better. 5 years
survival 57%
Kennedy JL
[66]
1985 Cancer 64 pts with
lymphoid lesions
of lung
12 patients
with primary
lymphoma
Heterogenous group of
patients
Median survival of 117
months if PLL. For
Disseminated lymphoma
median survival 33
months
Li G [67] 1990 Histopathology 62 cases. All B cell
but 2 cases of T-
cell lymphoma
43 cases of
MALT
32 of the MALTS
showed solitary or
multiple sharply defined
nodules
Recurrences in
46% of the MALTs
Constitutional symptoms
and T cell lymphoma
showed a bad prognosis.
Cordier JF
[68]
1993 Chest 70 nHL, no
mediastinal
adenopathy
Mean age 58.4
y, M:F 1:1,
majority non
smokers. 87%
Low grade.
majority
MALTs. 13%
high grade
Localized opacities 87%.
Mass -like appearance
24%, Bilateral disease
21%. Monoclonal
gammopathy 30%.
Metastasis 7 pts
(stomach, bone
marrow, spleen,
liver) interval
between Dx and
mets from 10
months to 7 years
69% underwent surgical
resection. Overall survival
93.6% at 5 years for low
grade L 26% treated with
chemotherapy alone
Ferraro P [69] 2000 Annals of
Thorac Surg
48 nHL MALTs 73%.
Mean age 61.8
years.
Symptoms
62.5% of
patients,
Mass lesion 60%,
Bilateral disease 44%.
Mediastinal-hilar
lymphadenopathy 31%.
Pleural effusions 15%.
IE: 37 patients, II2E:7,
II2EW:3, Stage III:1
Local recurrence
50%
Complete surgical
resection 40% overall.
Incomplete resection in
29 patients (21 patients
with bilateral disease)
73% of MALTs had
complete resection. Post
op Chemo 54%. Five
year survival for MALTs
68% and 10 years 53%..
Graham B
[70]
2005 Annals of
Thorac Surg
18 MALTs 78%.
Mean age 66.4
y M:F 1:2
Symptoms
78% of
patients,
Nodules or Mass lesions
72%, Bilateral disease
39%. Mediastinal-hilar
lymphadenopathy 39%.
Pleural effusions 22%.
IIE (39%) pts.
Median time to
disease recurrence
or death: 6 years
6% died of disease. Five
year survival > 80%
Hu YH [71] 2009 Ann Hematol 22 MALTs 54% Nodules or masses 73%.
Mediastinal
lymphadenopathy
MALTs/non-MALTs: 8/80
Patients who had surgery
tended to have better
survival. Five year survival
MALTs/Non-MALTs 91%
over 21%.
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mopathy is associated with worse prognosis [66].
The significant role of Broncho Alveolar Lavage (BAL)
with a cell count of plasma cells of 40% and lymphocytes
of 17% with prominence of CD19 positive lymphocytes
has been reported by Umino et al [51]. IgG/albumin ratio
13 times higher and IL-6/albumin ratio 29 times higher
in lavage fluid than in serum. Furthermore TBLB and
immunohistochemical stains mainly CD20 could be help-
ful. DNA extraction from the surgical specimen and PCR
reveals rearrangement band of the genes to the heavy
chain immunoglobulin (Fr3a & VLJH primers) [51]. The
diagnostic value of Cell surface markers analysis using
fresh tissue was also stated in some reports [35,65].
Staging workup should include bone marrow biopsy
and CT of the abdomen to exclude extrathoracic dis-
ease. Lymphangiograms and bone scans could be part of
the preoperative staging [65].
The role of PET scan is equivocal due to the low avid-
ity and the multifocal nature of the disease. The low
yield of bronchoscopy and Transcutaneous needle CT
guided biopsy has been stated in few reports [13,20].
There is however, a high role for VATS or open surgical
lung biopsy with a diagnostic yield more than 90%.
Histology
PLL arises from centrocyte-like cells normally present in
bronchus associated lymphoid tissue. Monomorphic cell
population and invasion of bronchial cartilage, pleura or
lymph nodes are suggestive of malignancy. Some cases
of PLL appeared as complications of a pre existing
dysimmune disease (Pigeon breeder disease), Gougerot-
Sjogren, Lymphomatoid granulomatosis (LYG) and Lie-
bows lymphomatoid granulomatosis) [12,19,32].
The gross classification of Low Grade malignant Lym-
phoma higher grade MALTomas (large cell type) and
others (ie. Follicular, Diffuse large B-cell, anaplastic
large cell)
has been used through out the literature. A detail
attempt to estimate the biological potential of lympho-
mas by their histologic type and correlate this with out-
come was attempted with the use of various systems of
histologic classification of non Hodgkins lymphomas.
Although from the surgeons prospective the classifica-
tion seems complicated, one could grossly divide the
tumors into small round lymphocytes (50-60%), with
varying degrees of plasmacytic change, ("plasmacytoid”
well differentiated) and large lymphocytic tumors.
More specifically the Kiel classification [32] essentially
differentiates Lymphoplasmacytic (LP) from Centroblas-
t i cl y m p h o m a( C B ) .T h eL Pt y p ei st h em o s tc o m m o n
(55-65%) [65]. The tumor is composed of uniform small
round lympocytes; they often grow as solid masses; infil-
tration of bronchial and vascular wall is often however
necrosis does not present. The incidence of recurrence
is less than 35% through out the literature [65].
Contrary CB type makes up 40% of the cases. It con-
sists of a centrocytic diffuse or follicular population
including the rare immunoblastic type. In general those
tumors are aggressive, present as pulmonary infiltrates
therefore are not amenable to surgical resection and
have a higher tendency to recur.
The term MALTomas was described by Bienenstock
et al [72]. They are the most common amongst nHL
(76% according to Cordier et al). The MALTomas are
characterized by: extranodal, small lymphocytic b-cell
tumor, cellular heterogeneity, infiltration of the bron-
chial mucosa by centrocyte cells and presence of reac-
tive lymphoid follicles. The etiology of this mucosal
transformation is probably acquired in response to long-
term exposure to various antigenic stimuli; Synchronus
MALTomaS involving the lung, stomach & ocular
adnexa have been reported in the literature [68,70].
Pulmonary lymphomas of nH type could be divided
into 4 groups [48]according to the properties and beha-
vior of the tumor: B-cells small or medium size (those
tumors are frequently associated with consolidations
and air bronchograms), B-cell large lymphoid cell (fre-
quently radiologic presentation is consistent with a
mass) and T-cell tumors (bad prognosis). Furthermore
the REAL classification sums up the histological varia-
tions of all types of lymphomas [73] however, from the
surgical prospective it is detailed and probably not
widely applicable.
Differentiating between Lymphoma (especially
Lymphoplasmacytic (LP) type) and pseudolymphoma
Mixture of mature lymphocytes and plasma cells with
reactive follicles are suggestive of pseudolymphoma.
Pulmonary pseudolymphoma is a rare lesion; Up till
1980, only 30 cases were reported in the literature. True
lymphoma was developed in four cases [34].
The diagnosis of pseudolymphoma is based on: 1) pul-
monary nodules composed of cytologically benign lym-
phoid cells 2) presence of infiltrates with plasma cells,
histiocytes and monocytes 3) presence of germinal cen-
ters. In addition, the presence of pleural effusion does
not preclude the diagnosis of pseudolymphoma.
Immunological studies aim to define whether the lym-
phoid proliferation is monoclonal or polyclonal. It is
suggested that PPL arises from centrocyte-like cells nor-
mally present in bronchus -associated lymphoid tissue.
In addition to malignant population reactive follicles
and polytypic plasma cells are frequently present so one
should be aware that cases previously diagnosed as
pseudo-lymphoma or lymphoid interstitial pneumonia
need to be reconsidered. Moreover when recurrent
tumors are present then pseudo L is rare; however
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course [18].
Surgical Treatment strategies
Resection rate varies from series to series [18,37,68,69].
There are no guidelines as to when surgery is indicated.
While reviewing the literature one gets the impression
that surgery is advocated on an institutional basis.
Surgery for solitary lesions and adjuvant therapies for
more extensive disease has been the general consensus.
Overall 60-70% of the patients with PLL are surgical
candidates [68]; however, incomplete resection is
reported to be the case in more than 50% of the cases
[69]. Surgical candidate could potentially be any patient
with locally resectable tumor up to stage II 2EW.
Lymph node involvement does not appear to be a con-
traindication to surgery. Likewise bilateral disease could
also be tackled surgically. However the surgical ablation
of such lesions must be economical [37] because of fre-
quent recurrence, sometimes bilateral. Hu et al [71]
concluded that patients who had received surgery
tended to have a better 5 year overall survival.
The MALTomas are slow growing tumors with an
indolent course; tent to be localized and therefore
amenable to surgery (73% complete resection was
achieved [69]).
Combined modality therapy appears to be superior in
patients with bulky disease, residual disease following
operation and an unfavorable non-MALT type of
histology.
Recurrence rates
Pulmonary recurrences are either within the ipsilateral
lung or in both lungs. Extrapulmonary recurrent disease
occurs mainly in lymph nodes, however skin, bone mar-
row or visceral organs could be affected [63,65].
T h eo v e r a l ll o c a lr e c u r r e n c er a t ei s5 0 %[ 6 9 ] .M o r e
specifically the incidence of recurrence for the LP group
is 33% with an average time of 69 months versus 50%
for the CB group [65].
The median time to disease recurrence or death has
been reported to be 6-7 years [70,68]. Late recurrences
up to 14 years have also been reported [23].
There are not enough data in the literature regarding
Surgery for recurrences; nevertheless the general con-
sensus dictates that recurrences should be treated with
aggressive chemotherapy regimes.
Survival data
This is a heterogenous group of patients. Nevertheless
the overall reported median time to death was 7 years
or the overall reported mean survival was 71.3 months.
More specifically for low grade lymphomas the median
survival was 117 months and for disseminated lym-
phoma 33 months according to Kennedy et al [66].
The overall survival at 3 years was 86% and at 5 years
57% [68,65]. For the MALTomas the five year survival
was 68% and the ten year 53% [69].
The prognostic factors influencing survival are: the
histologic type, T cell lymphoma [67] the presence of
pleural effusion [63] as well as bilateral disease and the
need for adjuvant therapy [70]. In contrary according to
Ferraro et al [69] complete Vs incomplete resection, the
stage of the disease, the presence of mediastinal lumph
node involvement or bilateral disease did not signifi-
cantly influence survival.
Discussion
Extensive literature review of the medical literature the
last 40 years was carried out. We have excluded cases of
primary pulmonary AIDS related lymphoma and lym-
phoma following immuno-suppression and transplanta-
tion (200 fold higher than the general population).
The incidence of PLL has two peaks: the first on in
the fifth decade of life and the second late six and
seventh decade. The diagnostic criteria for PLL include
bilateral pulmonary lesions as PPL. The reason for that
is the fact that several of those patients when treated
never showed evidence of extapulmonary involvement.
Also the definition includes absence of extrapulmonary
disease for 3 months following the initial diagnosis. This
is because invariably extrathoracic and extranodular
lymphoma may present (ie. Pulmonary and stomach
Lymphoma)
High index of suspicious facilitates the diagnosis of
this rare, indolent disease. One third of patients have no
symptoms, furthermore out of the symptomatic cohort
the duration of symptoms prior to the diagnosis is at
least 5 months. Serum protein electrophoresis abnorm-
alities are present in 33% of the patients [65].
The frequency of imagine features of PLL is difficult to
assess in the literature because of varying radiological ter-
minology & heterogeneity of several series including all
lymphomas of the lung. The radiography is non informa-
tive (solitary nodule, multiple ill defined nodules, consoli-
dated mass with air bronchograms, ground glass opacity
or reticular lesions in one or both lung fields, pleura effu-
sions, atelectasis and cavities) and non specific. Multiple
lesions can be present in up to 25% of the patients [65],
air space consolidation with air bronchograms is the
most frequent imaging in up to 65%-70% of the cases and
pleural effusions in 25% of the cases [31].
The histological classification having kept the princi-
ples of low grade (87% of the patients, as per Cordier et
al [68]) and high grade disease, has evolved into more
complex classifications taking into account the cell
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that does not necessarily correlate with prognosis the
gross differentiation into MALTs and non MALTs
somehow reflects prognosis [71].
The Staging systems considers bilateral pulmonary
lesion as stage I disease and stage II as disease confined
to the thoracic cavity;
Only surgical biopsy and resection obtains high yield
(64% of the patients as per Cordier et al [68] & 90% of
the patients as per Ferraro et al [69].
The prognostic factors affecting survival are not well
defined; the stage of the disease, extend of resection
(complete Vs incomplete) and the presence of mediast-
inal lymphadenopathy does is not associated with worse
prognosis [69]. In contrary, the report by Hu et al [71]
suggested that hilar or mediastinal node involvement
negatively influences survival. Higher stage disease was
associated with statistically not significantly worse out-
come according to Graham et al [70]. The authors
reported that bilateral disease was the most significant
factor predicting disease recurrence and death.
T h ee v a l u a t i o n so ft h er o l eo fs u r g e r ya sw e l la st h e
indications for surgery are scarce in the literature; posi-
tive surgical margins do not alter survival therefore the
role of surgery may be applicable in the majority of the
cases following by chemotherapy.
The long term outcome of PLL is favorable; 56% of
the patients recovered from the disease [70] with an
overall 5 year survival across the border of >60% and a
recurrence rate of less than 50%.
During the analysis of the presented series we
observed a low consistency in publishing specific vari-
ables (ie. Incidence of recurrence, etc) and this pre-
cluded us from carrying out detailed statistics; therefore
our paper carries the biases not only from the studies
examined but also from its observational character.
Nevertheless, we believe that our report has attempted
to give an insight in this rare and not well addressed
pathology.
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